Remarkable Bone Formation following Gefitinib for Extensive Lytic Bone Metastasis: A Report of Two Cases

Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib...

Full description

Bibliographic Details
Main Authors: Elrofai Suliman Bashir, Angel Khor Nee Kwan, Chris Yin Wei Chan, Mun Keong Kwan
Format: Article
Language:English
Published: SAGE Publishing 2016-12-01
Series:Journal of Orthopaedic Surgery
Online Access:https://doi.org/10.1177/1602400330
Description
Summary:Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
ISSN:2309-4990